SCHEMBL4354700

SCHEMBL4354700

CC(C)(C)CC(C)(C)NC(=O)Nc1ccc(O)cc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 1/20 0.48
MAPT P10636 5/20 0.46
POLB P06746 5/20 0.46
HTT P42858 4/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 3/20 0.41
LMNA P02545 1/20 0.41
CXCR2 P25025 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TP53 P04637 2/20 0.37
EPHX1 P07099 1/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
RECQL P46063 1/20 0.37
PLEC Q15149 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6566862 0.87 CXCR2 (0.54) MAPTPOLBHTTKMT2AMEN1
SCHEMBL4343813 0.83 CXCR1 (0.54) CXCR1MAPTPOLBHTTKMT2A
SCHEMBL6254271 0.82 RAB9A (0.55) CXCR1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL4348733 0.82 POLB (0.51) CXCR1MAPTPOLBHTTKMT2A
SCHEMBL6568668 0.82 GAA (0.61) MAPTPOLBHTTKMT2AMEN1
SCHEMBL6566923 0.77 IDO1 (0.52) MAPTPOLBHTTKMT2AMEN1
SCHEMBL4355807 0.77 KMT2A (0.54) MAPTPOLBHTTKMT2AMEN1
SCHEMBL6565514 0.77 POLB (0.66) MAPTPOLBHTTKMT2AMEN1
SCHEMBL6596633 0.75 SMN1; SMN2 (0.53) CXCR1MAPTPOLBHTTKMT2A
SCHEMBL6568647 0.74 HTT (0.41) MAPTPOLBHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CXCR1 832/4885MAPT 4439/4885POLB 3571/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CXCR1 1199/4885MAPT 4184/4885POLB 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.